Eli Lilly's weight loss-related drug Zepbound could potentially be used to reduce the severity of sleep apnea in adults with obesity, according to a recent study. Results of a phase three clinical trial, published Wednesday, showed that injections of the drug, either 10 mg or 15 mg, "significantly reduced the apnea-hypopnea index compared to placebo.
The adults who were evaluated were not on positive airway pressure therapy, which uses a machine to pump air under pressure into the lungs, for 52 weeks during the trial. Currently, tirzepatide is approved for chronic weight management and sold under the brand name Zepbound. It's also approved for treatment of Type 2 diabetes and sold under the brand name Mounjaro.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Eli Lilly’s weight loss drug Zepbound found to reduce sleep apnea, company saysBerkeley Lovelace Jr. is a health and medical reporter for NBC News. He covers the Food and Drug Administration, with a special focus on Covid vaccines, prescription drug pricing and health care. He previously covered the biotech and pharmaceutical industry with CNBC.
Source: NBCNewsHealth - 🏆 707. / 51 Read more »
Eli Lilly's Zepbound shows promise as a sleep apnea treatment in late-stage trialsThe pharmaceutical giant plans to present the trial data at an upcoming medical conference and submit them to the U.S. Food and Drug Administration mid-year.
Source: NBCPhiladelphia - 🏆 569. / 51 Read more »
Most doses of Eli Lilly's Zepbound, Mounjaro in short supply through June, FDA saysThe insatiable demand for weight loss and diabetes drugs is still trouncing supply, even as Eli Lilly and Novo Nordisk work to increase production capacity.
Source: CNBC - 🏆 12. / 72 Read more »
Stocks making the biggest premarket moves: Eli Lilly, Travelers, United Airlines, Alcoa and moreThese are the stocks posting the largest moves in the premarket.
Source: CNBC - 🏆 12. / 72 Read more »
Eli Lilly warns 2 of its insulin products may be out of stockThe shortage applies to the company's 10 mL vials of Humalog and Insulin Lispro Injection medications.
Source: 10News - 🏆 732. / 50 Read more »
Eli Lilly Warns That 2 Insulin Products Will Be in Short SupplyDrugmaker Eli Lilly & Co is announcing a temporary shortage of two of its insulin products.
Source: MedicineNet - 🏆 575. / 51 Read more »